Zobrazeno 1 - 10
of 130
pro vyhledávání: '"SGLT2-i"'
Autor:
Giuseppe Miceli, Maria Grazia Basso, Andrea Roberta Pennacchio, Elena Cocciola, Chiara Pintus, Mariagiovanna Cuffaro, Martina Profita, Giuliana Rizzo, Mariachiara Sferruzza, Antonino Tuttolomondo
Publikováno v:
Medicina, Vol 60, Iss 11, p 1796 (2024)
The impact of diabetic foot (DF) on the healthcare system represents a major public health problem, leading to a considerable clinical and economic burden. The factors contributing to DF’s development and progression are strongly interconnected, in
Externí odkaz:
https://doaj.org/article/c607ce21369d4ae58972a6b5d529de7b
Autor:
Selin Genc, Bahri Evren, Onur Selcuk Yigit, Ibrahim Sahin, Ramazan Dayanan, Aleksandra Klisic, Ayse Erturk, Filiz Mercantepe
Publikováno v:
Pharmaceuticals, Vol 17, Iss 11, p 1553 (2024)
Background/Objectives: The antidiabetic effect of SGLT2 inhibitors (SGLT2-is) is based on their ability to increase glucose excretion through urine by inhibiting the kidney-resident SGLT2 protein. Euglycemic diabetic ketoacidosis (EuDKA) is an uncomm
Externí odkaz:
https://doaj.org/article/f6ef8ffaac89426a8b8e8fd472a23393
Autor:
Maria Elena Lunati, Vincenzo Cimino, Davide Bernasconi, Alessandra Gandolfi, Paola Silvia Morpurgo, Camilla Tinari, Elisa Lazzaroni, Laura Baruffaldi, Milena Muratori, Laura Montefusco, Ida Pastore, Antonio Rossi, Ivano Giuseppe Franzetti, Fabrizio Muratori, Roberto Manfrini, Olga Eugenia Disoteo, Rosa Terranova, Paolo Desenzani, Angela Girelli, Renata Ghelardi, Francesca D’Addio, Moufida Ben Nasr, Cesare Berra, Franco Folli, Loredana Bucciarelli, Paolo Fiorina
Publikováno v:
Pharmacological Research, Vol 199, Iss , Pp 107040- (2024)
Dapagliflozin, a sodium-glucose co-transporter-2 inhibitor and semaglutide, a glucagon-like peptide 1 receptor agonist, have both demonstrated efficacy in glycemic control, reducing blood pressure, body weight, risk of renal and heart failure in type
Externí odkaz:
https://doaj.org/article/896fc8acef4049c186f0bd9af04fa581
Autor:
Celestino Sardu, Maria Consiglia Trotta, Ferdinando Carlo Sasso, Cosimo Sacra, Gerardo Carpinella, Ciro Mauro, Fabio Minicucci, Paolo Calabrò, Michele D’ Amico, Fabrizio D’ Ascenzo, Ovidio De Filippo, Mario Iannaccone, Carmine Pizzi, Giuseppe Paolisso, Raffaele Marfella
Publikováno v:
Cardiovascular Diabetology, Vol 22, Iss 1, Pp 1-15 (2023)
Abstract Background Sodium–glucose transporter 2 inhibitors (SGLT2-I) could modulate atherosclerotic plaque progression, via down-regulation of inflammatory burden, and lead to reduction of major adverse cardiovascular events (MACEs) in type 2 diab
Externí odkaz:
https://doaj.org/article/c47e5c4bbd454170b666cf4398702fcc
Autor:
Carmela Morace, Giuseppe Lorello, Federica Bellone, Cristina Quartarone, Domenica Ruggeri, Annalisa Giandalia, Giuseppe Mandraffino, Letteria Minutoli, Giovanni Squadrito, Giuseppina T. Russo, Herbert Ryan Marini
Publikováno v:
Metabolites, Vol 14, Iss 5, p 264 (2024)
An acute metabolic complication of diabetes mellitus, especially type 1, is diabetic ketoacidosis (DKA), which is due to an increase in blood ketone concentrations. Sodium/glucose co-transporter-2 inhibitor (SGLT2-i) drugs have been associated with t
Externí odkaz:
https://doaj.org/article/be5931ac75f945ee82fc76a935d673d3
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Pasquale Paolisso, Luca Bergamaschi, Gaetano Santulli, Emanuele Gallinoro, Arturo Cesaro, Felice Gragnano, Celestino Sardu, Niya Mileva, Alberto Foà, Matteo Armillotta, Angelo Sansonetti, Sara Amicone, Andrea Impellizzeri, Gianni Casella, Ciro Mauro, Dobrin Vassilev, Raffaele Marfella, Paolo Calabrò, Emanuele Barbato, Carmine Pizzi
Publikováno v:
Cardiovascular Diabetology, Vol 21, Iss 1, Pp 1-12 (2022)
Abstract Background The inflammatory response occurring in acute myocardial infarction (AMI) has been proposed as a potential pharmacological target. Sodium-glucose co-transporter 2 inhibitors (SGLT2-I) currently receive intense clinical interest in
Externí odkaz:
https://doaj.org/article/49e0b66285c34ee69726e89ede002ffb
Publikováno v:
European Journal of Medicinal Chemistry Reports, Vol 6, Iss , Pp 100074- (2022)
Diabetes mellitus (DM) is one of the leading causes of death by World Health Organization in 2019 and is considered a significant cause of other diseases including heart attack, stroke, kidney failure, blindness, and lower limb amputation. Sodium glu
Externí odkaz:
https://doaj.org/article/01ca18e8a21d49989b44186e0c0448ed
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.